These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 32097059)

  • 1. A Bayesian approach to benefit-risk assessment in clinical studies with longitudinal data.
    Yan D; Ahn C; Azadeh S; Atlas M; Tiwari R
    J Biopharm Stat; 2020 May; 30(3):574-591. PubMed ID: 32097059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semiparametric Bayesian inference on skew-normal joint modeling of multivariate longitudinal and survival data.
    Tang AM; Tang NS
    Stat Med; 2015 Feb; 34(5):824-43. PubMed ID: 25404574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A semiparametric Bayesian approach to the random effects model.
    Kleinman KP; Ibrahim JG
    Biometrics; 1998 Sep; 54(3):921-38. PubMed ID: 9750242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dirichlet negative multinomial regression for overdispersed correlated count data.
    Farewell DM; Farewell VT
    Biostatistics; 2013 Apr; 14(2):395-404. PubMed ID: 23221819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian approach for assessing noninferiority in a three-arm trial with binary endpoint.
    Ghosh S; Tiwari RC; Ghosh S
    Pharm Stat; 2018 Jul; 17(4):342-357. PubMed ID: 29473291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semiparametric Bayesian analysis of censored linear regression with errors-in-covariates.
    Sinha S; Wang S
    Stat Methods Med Res; 2017 Jun; 26(3):1389-1415. PubMed ID: 25882297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis using Dirichlet process.
    Muthukumarana S; Tiwari RC
    Stat Methods Med Res; 2016 Feb; 25(1):352-65. PubMed ID: 22802045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semiparametric bayesian testing procedure for noninferiority trials with binary endpoints.
    Osman M; Ghosh SK
    J Biopharm Stat; 2011 Sep; 21(5):920-37. PubMed ID: 21830923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling disease incidence data with spatial and spatio temporal dirichlet process mixtures.
    Kottas A; Duan JA; Gelfand AE
    Biom J; 2008 Feb; 50(1):29-42. PubMed ID: 17926327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian joint modeling of longitudinal measurements and time-to-event data using robust distributions.
    Baghfalaki T; Ganjali M; Hashemi R
    J Biopharm Stat; 2014; 24(4):834-55. PubMed ID: 24697192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian approach to noninferiority trials for proportions.
    Gamalo MA; Wu R; Tiwari RC
    J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Dirichlet-Multinomial Bayes Classifier for Disease Diagnosis with Microbial Compositions.
    Gao X; Lin H; Dong Q
    mSphere; 2017; 2(6):. PubMed ID: 29242838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An integrative Bayesian Dirichlet-multinomial regression model for the analysis of taxonomic abundances in microbiome data.
    Wadsworth WD; Argiento R; Guindani M; Galloway-Pena J; Shelburne SA; Vannucci M
    BMC Bioinformatics; 2017 Feb; 18(1):94. PubMed ID: 28178947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semi-parametric Bayesian regression for subgroup analysis in clinical trials.
    Gamalo-Siebers M; Tiwari R
    J Biopharm Stat; 2019; 29(6):1024-1042. PubMed ID: 30747568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.
    Jiang Z; Song Y; Shou Q; Xia J; Wang W
    Trials; 2014 Dec; 15():500. PubMed ID: 25528466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new Bayesian joint model for longitudinal count data with many zeros, intermittent missingness, and dropout with applications to HIV prevention trials.
    Wu J; Chen MH; Schifano ED; Ibrahim JG; Fisher JD
    Stat Med; 2019 Dec; 38(30):5565-5586. PubMed ID: 31691322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global benefit-risk assessment in designing clinical trials and some statistical considerations of the method.
    Pritchett YL; Tamura R
    Pharm Stat; 2008; 7(3):170-8. PubMed ID: 17538942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian monitoring of clinical trials with failure-time endpoints.
    Rosner GL
    Biometrics; 2005 Mar; 61(1):239-45. PubMed ID: 15737099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Bayesian expected power via Bayesian bootstrap.
    Liu F
    Stat Med; 2018 Oct; 37(24):3471-3485. PubMed ID: 29938832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian variable selection in linear quantile mixed models for longitudinal data with application to macular degeneration.
    Ji Y; Shi H
    PLoS One; 2020; 15(10):e0241197. PubMed ID: 33104698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.